title: Targeting the tumor mutanome for personalized vaccination therapy.
abstract: Next generation sequencing enables identification of immunogenic tumor mutations targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor control, qualifying mutated epitopes as source for effective vaccines.
authors.affiliation: TRON-Translational Oncology at the University Medical Center Mainz; Mainz, Germany.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Kreiter
authors.forename: John C
authors.initials: JC
authors.lastname: Castle
authors.forename: Ozlem
authors.initials: O
authors.lastname: Türeci
authors.forename: Ugur
authors.initials: U
authors.lastname: Sahin